cancer

How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals
How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals
Investors Business Daily
Merck
Keytruda
cancer
Flag link:
MD Anderson and Boehringer Ingelheim to Partner on Cancer, Found a Virtual R&D Center
MD Anderson and Boehringer Ingelheim to Partner on Cancer, Found a Virtual R&D Center
BioSpace
Boehringer Ingelheim
MD Anderson Cancer Center
cancer
R&D
Flag link:
AstraZeneca cancer drugs build as primary care shrinks
AstraZeneca cancer drugs build as primary care shrinks
Biopharma Dive
AstraZeneca
cancer
oncology
primary care
Tagrisso
Symbicort
Lynparza
Flag link:
Revealing the true value of new cancer drugs to payers
Revealing the true value of new cancer drugs to payers
Pharmaforum
CAR-T
cancer
payers
Flag link:
Guardant’s blood test tracks microsatellite instability status on par with tissue biopsy in new study
Guardant’s blood test tracks microsatellite instability status on par with tissue biopsy in new study
Fierce Biotech
Guardant Health
biomarkers
diagnostics
DNA
cancer
solid tumors
Flag link:
Sales gap grows between rival Merck, Bristol cancer therapies
Sales gap grows between rival Merck, Bristol cancer therapies
Biopharma Dive
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
cancer
Flag link:
NEC buys OncoImmunity to boost AI-based cancer research
NEC buys OncoImmunity to boost AI-based cancer research
Pharmaforum
NEC
M&A
OncoImmunity
artificial intelligence
machine learnings
R&D
cancer
Flag link:
How $2.8B Genomic Health deal catapults Exact beyond Cologuard
How $2.8B Genomic Health deal catapults Exact beyond Cologuard
BioCentury
EXACT Sciences
M&A
Genomic Health
Cologuard
cancer
diagnostics
Flag link:
FDA approves Rituxan biosimilar
FDA approves Rituxan biosimilar
Beckers Hospital Review
Pfizer
biosimilars
FDA
Ruxience
cancer
autoimmune disease
Genentech
Flag link:
Did cancer clinical trials stay on track at ASCO 2019?
Did cancer clinical trials stay on track at ASCO 2019?
Pharmaforum
ASCO
clinical trials
cancer
ASCO 2019
bladder cancer
breast cancer
prostate cancer
pancreatic cancer
Flag link:
Denmark's Genmab hits the jackpot with $500M+ US IPO as smaller biotechs rake in a combined $147M
Denmark's Genmab hits the jackpot with $500M+ US IPO as smaller biotechs rake in a combined $147M
Endpoints
Genmab
IPOs
cancer
Flag link:
In a small study, a cancer vaccine assist beats immunotherapy drugs alone
In a small study, a cancer vaccine assist beats immunotherapy drugs alone
Stat
cancer vaccines
vaccines
Neon Therapeutics
cancer
metastatic non-small-cell lung cancer
metastatic bladder cancer
immunotherapy
Flag link:
Researchers Find Key Mechanism Behind How Cancer Spreads
Researchers Find Key Mechanism Behind How Cancer Spreads
BioSpace
cancer
mEAK-7
mTOR
metastatic cancer
Flag link:
Boosting CAR-T to treat solid tumors with a vaccine
Boosting CAR-T to treat solid tumors with a vaccine
Fierce Biotech
vaccines
CAR-T
cancer
cancer vaccines
Elicio
solid tumors
Flag link:
Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit
Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit
Stat
Christi Shaw
Kite Pharma
Gilead Sciences
cancer
Pharma CEOs
Flag link:
Cancer deaths cost the U.S. $94 billion in lost earnings in a single year
Cancer deaths cost the U.S. $94 billion in lost earnings in a single year
Stat
cancer
cancer deaths
Flag link:
French Biotech to Develop Anti-Cancer Drugs with Measles Virus
French Biotech to Develop Anti-Cancer Drugs with Measles Virus
Xtalks
drug development
France
cancer
Oncovita
measles
Flag link:
Another Biosimilar Approval From FDA, Another Unknown Launch Date
Another Biosimilar Approval From FDA, Another Unknown Launch Date
RAPS.org
Pfizer
Zirabev
biosimilars
FDA
Roche
cancer
Avastin
Flag link:
Adaptive Biotechnologies Updates IPO Filing – Will Raise Up To $327 Million
Adaptive Biotechnologies Updates IPO Filing – Will Raise Up To $327 Million
CP Wire
Adaptive Biotechnologies
IPOs
cancer
Flag link:
Gilead to add lipid kinase inhibitors to pipeline via Carna deal
Gilead to add lipid kinase inhibitors to pipeline via Carna deal
BioCentury
Gilead Sciences
Carna
lipid kinase inhibitors
cancer
Flag link:

Pages